Erlotinib

• Verfasst von: Steins, Martin [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Geißler, Michael [VerfasserIn]
• Titel: Erlotinib
• Verf.angabe: M. Steins, M. Thomas, M. Geissler
• E-Jahr: 2014
• Jahr: 23 April 2014
• Umfang: 15 S.
• Fussnoten: Gesehen am 06.11.2020
• Titel Quelle: Enthalten in: Small molecules in oncology
• Ausgabe Quelle: 2nd ed. 2014
• Ort Quelle: Berlin, Heidelberg : Springer, 2014
• Jahr Quelle: 2014
• Band/Heft Quelle: (2014), Seite 109-123
• ISBN Quelle: 978-3-642-54490-3
• DOI: doi:10.1007/978-3-642-54490-3_6
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Animals
• Sach-SW: Antineoplastic Agents
• Sach-SW: Carcinoma, Hepatocellular
• Sach-SW: Carcinoma, Non-Small-Cell Lung
• Sach-SW: ErbB Receptors
• Sach-SW: Erlotinib Hydrochloride
• Sach-SW: Humans
• Sach-SW: Liver Neoplasms
• Sach-SW: Lung Neoplasms
• Sach-SW: Pancreatic Neoplasms
• Sach-SW: Protein Kinase Inhibitors
• Sach-SW: Quinazolines
• K10plus-PPN: 1738063828

Abstract

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways such as cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of them are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.